Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
GYRE Gyre Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: GYRE
Price (delayed)
$11.35
Market cap
$1.06B
P/E Ratio
141.88
Dividend/share
N/A
EPS
$0.08
Enterprise value
$1.05B
catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic
Highlights
The company's equity rose by 20% YoY and by 8% QoQ
The net income has soared by 108% YoY but it has contracted by 40% from the previous quarter
GYRE's EPS has surged by 106% year-on-year but it is down by 43% since the previous quarter
GYRE's revenue is down by 13% year-on-year and by 4.8% since the previous quarter
GYRE's gross profit is down by 13% year-on-year and by 4.9% since the previous quarter
Key stats
What are the main financial stats of GYRE
Market
Valuations
Earnings
Shares outstanding
93.76M
Market cap
$1.06B
Enterprise value
$1.05B
Price to earnings (P/E)
141.88
Price to book (P/B)
15.6
Price to sales (P/S)
9.75
EV/EBIT
96.16
EV/EBITDA
78.67
EV/Sales
10.44
Revenue
$100.64M
Gross profit
$96.84M
Operating income
$10.37M
Net income
$7.25M
EBIT
$10.93M
EBITDA
$13.36M
Free cash flow
-$8.51M
Per share
Balance sheet
Liquidity
EPS
$0.08
EPS diluted
$0.02
Free cash flow per share
-$0.1
Book value per share
$0.73
Revenue per share
$1.16
TBVPS
$1.44
Total assets
$129.79M
Total liabilities
$25.49M
Debt
$1.59M
Equity
$68.12M
Working capital
$49.46M
Debt to equity
0.02
Current ratio
3.6
Quick ratio
2.76
Net debt/EBITDA
-1.01
Margins
Efficiency
Dividend
EBITDA margin
13.3%
Gross margin
96.2%
Net margin
7.2%
Operating margin
10.3%
Return on assets
5.8%
Return on equity
11.4%
Return on invested capital
11.7%
Return on capital employed
9.9%
Return on sales
10.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GYRE stock price
How has the Gyre Therapeutics stock price performed over time
Intraday
3.75%
1 week
19.1%
1 month
42.95%
1 year
-25.77%
YTD
-6.2%
QTD
47.02%
Financial performance
How have Gyre Therapeutics's revenue and profit performed over time
Revenue
$100.64M
Gross profit
$96.84M
Operating income
$10.37M
Net income
$7.25M
Gross margin
96.2%
Net margin
7.2%
The company's operating margin has surged by 118% YoY but it fell by 33% QoQ
GYRE's operating income has surged by 116% year-on-year but it is down by 36% since the previous quarter
Gyre Therapeutics's net margin has surged by 109% YoY but it has decreased by 37% QoQ
The net income has soared by 108% YoY but it has contracted by 40% from the previous quarter
Price vs fundamentals
How does GYRE's price correlate with its fundamentals
Growth
What is Gyre Therapeutics's growth rate over time
Valuation
What is Gyre Therapeutics stock price valuation
P/E
141.88
P/B
15.6
P/S
9.75
EV/EBIT
96.16
EV/EBITDA
78.67
EV/Sales
10.44
GYRE's EPS has surged by 106% year-on-year but it is down by 43% since the previous quarter
GYRE's P/B is 139% above its 5-year quarterly average of 6.3 but 6% below its last 4 quarters average of 16.0
The company's equity rose by 20% YoY and by 8% QoQ
GYRE's revenue is down by 13% year-on-year and by 4.8% since the previous quarter
The stock's price to sales (P/S) is 6% more than its last 4 quarters average of 8.9 and 4.3% more than its 5-year quarterly average of 9.0
Efficiency
How efficient is Gyre Therapeutics business performance
GYRE's return on sales has surged by 116% year-on-year but it is down by 34% since the previous quarter
GYRE's ROIC has soared by 105% YoY but it is down by 41% from the previous quarter
Gyre Therapeutics's ROA has soared by 104% YoY but it has decreased by 41% from the previous quarter
The ROE has soared by 101% year-on-year but it has declined by 43% since the previous quarter
Dividends
What is GYRE's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history
Special dividends are included in TTM DPS and yield
Financial health
How did Gyre Therapeutics financials performed over time
The company's total liabilities fell by 23% YoY and by 6% QoQ
GYRE's current ratio is up by 12% year-on-year and by 8% since the previous quarter
Gyre Therapeutics's debt is 98% lower than its equity
Gyre Therapeutics's debt to equity has decreased by 33% QoQ
The company's equity rose by 20% YoY and by 8% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.